PlantForm

What PlantForm does

PlantForm Corporation is a privately-held Canadian biopharmaceutical company founded in 2008 that develops and manufactures biologic drugs using a proprietary plant-based expression platform called vivoXPRESS®. The platform uses genetically modified Nicotiana benthamiana (tobacco) plants as bioreactors to produce monoclonal antibodies, therapeutic proteins, and vaccines, with company-claimed manufacturing cost reductions of up to 90% and development timelines as short as six weeks versus traditional mammalian cell systems. The company's intellectual property is protected by seven patent families with seven issued or allowed patents covering the core platform, glycosylation engineering, and product-specific applications. Its pipeline spans biosimilar versions of Keytruda® (pembrolizumab), Lucentis® (ranibizumab), and Herceptin® (trastuzumab); medical countermeasures including an anti-ricin antibody (hD9) and recombinant butyrylcholinesterase (BuChE) for nerve agent protection; animal health products such as a PEDv vaccine, E. coli antibody feed additive, and avian influenza H5/H7 antigens; and emerging programs in recombinant human collagen and plant-made artificial exosomes.

The company serves three primary customer categories: government defense and biodefense agencies (Defence Research and Development Canada, USAMRIID, NRC-IRAP), pharmaceutical and biotech firms seeking low-cost biosimilar production, and contract development and manufacturing (CDMO) clients. Revenue mechanics combine non-dilutive government grants and contracts, technology licensing, joint ventures (notably the PlantPraxis JV in Brazil with PharmaPraxis/Axis Biotec Brasil), biosimilar co-development arrangements, and CDMO service fees. The company operates two Canadian sites—a headquarters at 1920 Yonge Street in Toronto and an R&D facility at The Research Park in Sarnia, Ontario—with an employee count of 11–50 and active collaborations extending into Brazil, South Africa, Thailand, and South Korea.

Name

PlantForm

Legal name

PlantForm Corporation

Website

https://plantformcorp.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

PlantForm Corporation is a Canadian biopharmaceutical company that uses its proprietary vivoXPRESS® plant-based manufacturing platform to produce biosimilar antibodies, medical countermeasures, and animal health products at significantly lower cost than mammalian cell systems.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Plant-based biopharmaceuticals
• Biosimilar development
• CDMO services
• Monoclonal antibodies
• Medical countermeasures

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization services offering the vivoXPRESS® platform to other parties for production of antibodies and proteins under contract arrangements.
2. Technology Licensing: Licensing arrangements for use of proprietary plant-based manufacturing platform technology.
3. Government Contracts: Funding and contracts from government agencies including Defence Research and Development Canada, USAMRIID, and NRC-IRAP for development of medical countermeasures and therapeutics.
4. Biosimilar Drug Development: Development and potential commercialization of biosimilar versions of approved biologic drugs including Keytruda, Lucentis, and other niche indication drugs.
5. Joint Ventures: Revenue through joint ventures such as PlantPraxis (with PharmaPraxis/Axis Biotec Brasil) for development and commercialization of biosimilars for specific markets like Brazil.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

PlantForm Corporation develops and commercializes the proprietary vivoXPRESS® plant-based biopharmaceutical manufacturing platform, which uses genetically modified Nicotiana (tobacco) plants as bioreactors to produce monoclonal antibodies, therapeutic proteins, and vaccines. The company also offers Contract Development and Manufacturing Organization (CDMO) services, biosimilar drug candidates (Keytruda, Lucentis, Herceptin biosimilars), medical countermeasures (anti-ricin antibody, BuChE), and animal health products using this platform.

Product overview

PlantForm Corporation is a biopharmaceutical company offering the proprietary vivoXPRESS® plant-based manufacturing platform for low-cost, rapid production of biologics including monoclonal antibodies, therapeutic proteins, and vaccines. The company's portfolio consists of: (1) the core vivoXPRESS® platform for plant-based expression in Nicotiana plants; (2) a pipeline of biosimilar drug candidates including Keytruda® (pembrolizumab), Lucentis® (ranibizumab), and Herceptin® (trastuzumab) for cancer and eye disease treatment; (3) medical countermeasures including anti-ricin antibody antidote and butyrylcholinesterase (BuChE) for nerve agent protection; (4) animal health products including PEDv vaccine and E. coli antibody feed additives; and (5) CDMO contract manufacturing services. Recent collaborations include avian influenza antigen production and artificial exosome development for therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• vivoXPRESS®: Proprietary plant-based biopharmaceutical manufacturing platform technology that produces biologic drugs in tobacco plants at significantly reduced cost compared to mammalian cell systems.

Products and services

• vivoXPRESS® Platform Proprietary plant-based biopharmaceutical manufacturing platform that enables rapid development and production of specialty antibody and protein drugs using genetically modified tobacco plants (Nicotiana sp.), offering faster timelines (as little as six weeks), lower costs (up to 90% reduction), and scalable production with mammalian glycosylation.
• CDMO Services Contract Development and Manufacturing Organization services offering the vivoXPRESS® technology platform to other parties for production of antibodies and proteins under contract and licensing arrangements.
• Ricin Antidote (Anti-ricin antibody hD9) Innovative plant-made antidote to ricin exposure developed using the vivoXPRESS® platform, with testing conducted in collaboration with Defence Research and Development Canada (DRDC) and USAMRIID.
• Biosimilar Pembrolizumab (Keytruda®) Biosimilar version of Keytruda® (pembrolizumab) for cancer treatment, being developed under collaboration with Bio-Manguinhos/Fiocruz in Brazil for the Latin American market.
• Biosimilar Ranibizumab (Lucentis®) Biosimilar version of Lucentis® (ranibizumab) for eye disease treatment, being developed for niche indication markets.
• Biosimilar Trastuzumab (Herceptin®) Biosimilar version of Herceptin® (trastuzumab) for breast cancer treatment, demonstrated comparable efficacy to originator in mouse studies.
• Recombinant Butyrylcholinesterase (BuChE) Plant-produced enzyme developed as a bioscavenger for prophylactic protection against nerve agents such as sarin gas, with ongoing research for sialylated versions to improve pharmacokinetics.
• Avian Influenza Antigens (H5 and H7) Plant-based produced avian influenza H5 and H7 antigens for diagnostic testing, being developed in collaboration with Smart Biotech for commercial bird operations in South Africa.
• Porcine Epidemic Diarrhea Virus (PEDv) Vaccine Vaccine candidate to prevent Porcine Epidemic Diarrhea Virus infections in pigs, developed in collaboration with Agriculture and Agri-Food Canada (AAFC).
• E. coli Antibody (Feed Additive) Antibody feed additive to prevent E. coli infections in pigs, developed to improve livestock health and human food safety.
• Recombinant Human Collagen Plant-based recombinant human collagen using synthetic biology via the vivoXPRESS® platform for scalable production of properly hydroxylated human collagen in plants, targeting various markets including biomedical and cosmetics.

Quantifiable outcome

• Manufacturing cost reduction of up to 90% compared to mammalian cell systems
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

23 partnerships are on record, tiered core and minor.

• Baiya Phytopharm Co. Ltd.coreStrategic or Co-development Partner · 29 April 2025Three-way collaboration with The DABOM to develop plant-made artificial exosomes for therapeutics and drug delivery. PlantForm designs and synthesizes CD9 gene using vivoXPRESS platform. Baiya expresses and purifies recombinant CD9 in N. benthamiana plants using BaiyaPharming platform. Project aims to overcome scalability barriers in artificial exosome production.
• The DABOM Inc.coreStrategic or Co-development Partner · 29 April 2025Korean company using AI and microfluidics for mass production of artificial exosomes. Part of three-way collaboration to develop exosomes for cancer and neurodegenerative disease treatments. The DABOM produces artificial exosomes and compares them to natural exosomes.
• Smart BiotechcoreStrategic or Co-development Partner · 26 March 2025Research project to evaluate plant-based production of avian influenza H5 and H7 antigens for diagnostic test kit development. PlantForm will use vivoXPRESS platform to express antigens for commercial bird operations in South Africa. Project addresses need for diagnostic tests that can distinguish vaccinated from infected birds.
• Agriculture and Agri-Food Canada (AAFC)minorStrategic or Co-development Partner · 17 June 2024Research funding to develop vaccine for porcine epidemic diarrhea virus (PEDv) and E. coli infections in pigs.
• 3DBioFibRminorStrategic or Co-development Partner · 18 January 2024NGen funding collaboration to advance recombinant human collagen fiber manufacturing technology.
• SwiftPharmacoreStrategic or Co-development Partner · 14 November 2023Global licensing agreement and contract manufacturing agreement for plant-made biosimilars targeting blockbuster cancer drugs.
• AntoXa CorporationcoreStrategic or Co-development Partner · 5 September 2023Exclusive collaboration for development and commercialization of plant-made antibody against ricin exposure. AntoXa received Defence R&D Canada license for anti-ricin antibody technology.
• Bio-Manguinhos/FiocruzcoreStrategic or Co-development Partner · 7 March 2023Agreement to develop biosimilar pembrolizumab cancer drug and additional products for Brazilian market.
• Cape Biologix TechnologiesminorStrategic or Co-development Partner · 16 November 2020Agreement to commercialize COVID-19 antibody blood test.
• Inno-3BminorStrategic or Co-development Partner · 16 November 2020Agreement to commercialize COVID-19 antibody blood test.
• South Africa's CSIRminorStrategic or Co-development Partner · 17 July 2018Research collaboration with BGM Pharmaceuticals for plant-based protein production.
• McMaster UniversityminorStrategic or Co-development Partner · 27 February 2018NSERC Engage Grant research collaboration.
• University of Guelph (GlycoNet)minorStrategic or Co-development Partner · 13 December 2017GlycoNet grant for research partnership.
• University of CalgaryminorStrategic or Co-development Partner · 6 November 2017NSERC Engage Grant research collaboration.
• University of New MexicominorStrategic or Co-development Partner · 13 December 2016Filoviridae glycoprotein project collaboration.
• Université de Montréal (Dr. Andrés Finzi)minorStrategic or Co-development Partner · 12 December 2016Collaboration on HIV antibody elimination assays to determine efficacy of plant-based antibody cocktails for killing infected CD4+ T cells.
• Axis Biotec Brasil / PharmaPraxiscoreStrategic or Co-development Partner · 2 June 2016Joint venture (PlantPraxis) established to develop, manufacture, and commercialize biosimilar and biobetter versions of key biologic drugs for Brazilian market. Received US$1 million Finep grant for Humira biosimilar development and pilot manufacturing facility.
• University of Guelph (CESRF)coreStrategic or Co-development Partner · 3 March 2016NSERC Collaborative Research and Development Grant ($300K from NSERC, $378K from PlantForm) to optimize plant production of therapeutic antibodies. Three-year project with Dr. Mike Dixon's Controlled Environment Systems Research Facility.
• Defence Research and Development Canada (DRDC)coreStrategic or Co-development Partner · 8 February 2016Government contract for plant-based production of anti-ricin antibody (hD9). DRDC conducted in vitro and in vivo studies showing plant-made antibody efficacy comparable to mammalian-produced version.
• Ryerson University (Dr. Warren Wakarchuk)minorStrategic or Co-development Partner · 28 October 2015Collaboration on sialylation of plant-made BuChE for optimal bloodstream activity.
• University of CalgaryminorStrategic or Co-development Partner · 19 May 2015NSERC Engage Grant to assess CRISPR technology for improving tobacco-plant production of therapeutic proteins with Dr. Dae-Kyun Ro.
• Miami Mice Research CorpminorStrategic or Co-development Partner · 31 March 2015Collaboration to develop innovative mouse model for testing HIV antibodies.
• U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)coreStrategic or Co-development Partner · 22 December 2014Cooperative Research and Development Agreement for production and testing of Ebola Sudan antibodies using PlantForm's vivoXPRESS system. USAMRIID provides amino acid sequences and conducts evaluation of resulting material.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

Emerging players

• Mapp Biopharmaceutical: US biopharma focused on antibody-based countermeasures against infectious disease and biothreats — comparable to PlantForm's anti-ricin hD9, Ebola Sudan, and BuChE medical countermeasure programs and biodefense customer relationships.
• Leaf Expression Systems: UK-based plant expression company offering transient expression services in Nicotiana benthamiana — directly comparable plant-based CDMO/protein production technology to vivoXPRESS®, with overlapping academic and pharma client base.
• Cape Biologix Technologies: South African plant-based protein expression company developing diagnostics and reagents using Nicotiana — comparable to PlantForm's avian influenza antigen and COVID-19 antibody test work, but focused on diagnostic rather than therapeutic applications.

Broad incumbents

• Lonza Biologics: Global leader in mammalian-cell-based contract biologics manufacturing — represents the established incumbent CDMO benchmark against which PlantForm's plant-based CDMO must compete for pharma contract manufacturing work.
• Bio-Manguinhos / Fiocruz: Brazilian public-sector biopharmaceutical manufacturer partnered with PlantForm on biosimilar pembrolizumab — a strategic collaborator and broader incumbent in Latin American biologics manufacturing with similar biosimilar development mission.

Direct peers

• Kentucky BioProcessing (KBP): Plant-based protein and vaccine CDMO owned by British American Tobacco, using tobacco-plant expression for rapid biologics production — a direct competitor in plant-made pharmaceuticals with overlapping government/biodefense work.
• Medicago: Canadian biopharmaceutical company that uses Nicotiana-based plant expression to produce vaccines and therapeutic proteins — the closest direct peer to PlantForm's vivoXPRESS® platform, both in core technology and in government/defense customer focus.
• Protalix BioTherapeutics: Plant-cell-based biopharmaceutical company (using carrot cell bioreactors, ProCellEx) developing approved biologic drugs — shares the plant-based biologics development and commercial model with PlantForm, though using cell suspension rather than whole-plant systems.
• iBio: US-based plant-based biopharmaceutical CDMO offering contract manufacturing of proteins and antibodies using a proprietary plant expression platform — directly comparable to PlantForm's CDMO services and biologics pipeline.
• Baiya Phytopharm: Thailand-based company using Nicotiana benthamiana (BaiyaPharming) plant-based expression to produce therapeutic proteins — an active PlantForm collaborator and direct peer in plant-made biologics for emerging-market applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/plantformcorp
• YouTubeyoutube.com/channel/UC
• Facebookfacebook.com/PlantFormCorp
• LinkedInlinkedin.com/company/plantform-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PlantForm